Gene therapy for multiple myeloma that has returned or not responded
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new gene therapy for people with multiple myeloma that has come back or hasn't improved with other treatments. It aims to see if the therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that has returned or not responded to treatment.
- You have measurable signs of the disease (like certain blood or urine tests).
- You are able to take care of yourself (ECOG score 0 or 1).
- You have not had certain infections like hepatitis B, hepatitis C, or HIV.
- You have not had cancer treatment recently without a proper break.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests an investigational cell therapy called UB-VV500 combined with rapamycin, a drug that may help the therapy work better. It is for people whose multiple myeloma has come back or stopped responding to prior treatments. The goal is to see if this combination is safe and effective.
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
This early-phase trial tests an investigational cell therapy called LVIVO-TaVec122 for people with certain blood cancers (lymphoma or leukemia) that have come back or not responded to previous treatments. The goal is to see if this new treatment is safe and works for you.
This trial tests a new cell therapy (KSVCBD) for people with multiple myeloma that has returned or not responded to other treatments. It may help if your cancer cells have certain markers, CD19 or BCMA.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.